KemPharm, Inc. (NASDAQ: KMPH – Get a rating) – HC Wainwright Research analysts cut their earnings per share estimates for KemPharm for fiscal year 2024 in a note to investors on Monday, November 14. HC Wainwright analyst O. Livnat now expects the specialty pharmaceutical company to earn $0.01 per share for the year, down from its previous estimate of $0.03. HC Wainwright has a “Buy” rating and a price target of $10.00 on the stock. The consensus estimate of KemPharm’s current annual earnings is ($0.66) per share. HC Wainwright also released estimates for KemPharm’s fiscal year 2026 earnings at $1.66 EPS.
Several other research companies have also recently published reports on KMPH. Canaccord Genuity Group reduced its price target on KemPharm from $20.00 to $19.00 in a Thursday, November 10 research report. Canaccord Genuity Group began covering KemPharm in a research report on Thursday, September 15. They issued a “buy” rating and a price target of $20.00 for the company. To finish, StockNews.com upgraded KemPharm from a “hold” rating to a “sell” rating in a research report on Friday.
KemPharm is trading down 1.7%
NASDAQ: KMPH opened at $4.65 on Tuesday. The stock has a fifty-day moving average price of $5.80 and a two-hundred-day moving average price of $5.28. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt ratio of 0.14. KemPharm has a 1 year minimum of $4.00 and a 1 year maximum of $9.43.
Institutional entries and exits
A number of hedge funds have recently changed their positions in KMPH. Martingale Asset Management LP increased its stake in KemPharm shares by 19.6% during the first quarter. Martingale Asset Management LP now owns 75,612 shares of the specialty pharmaceutical company valued at $381,000 after acquiring an additional 12,412 shares in the last quarter. HealthInvest Partners AB increased its stake in KemPharm shares by 162.7% during the second quarter. HealthInvest Partners AB now owns 670,000 shares of the specialty pharmaceutical company valued at $2,988,000 after acquiring an additional 415,000 shares in the last quarter. Mystic Asset Management Inc. increased its stake in KemPharm shares by 44.6% during the first quarter. Mystic Asset Management Inc. now owns 104,081 shares of the specialty pharmaceutical company valued at $523,000 after acquiring 32,100 additional shares in the last quarter. Retirement Planning Co of New England Inc. increased its stake in KemPharm shares by 5.2% during the third quarter. Retirement Planning Co of New England Inc. now owns 302,820 shares of the specialty pharmaceutical company valued at $1,889,000 after acquiring 14,900 additional shares in the last quarter. Finally, Laurion Capital Management LP acquired a new equity stake in KemPharm during the second quarter at a value of $2,597,000. Hedge funds and other institutional investors hold 20.85% of the company’s shares.
About KemPharm
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company uses its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
Featured Articles
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected].
Before you consider KemPharm, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market spreads…and KemPharm wasn’t on the list.
While KemPharm currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.